Huan Zhao1, Yijia Liu1, Zhu Li1, Yanqi Song1, Xuemeng Cai1, Yuechen Liu1, Tianpu Zhang1, Liu Yang1, Lin Li1, Shan Gao1, Yubo Li2, Chunquan Yu3. 1. Tianjin University of Traditional Chinese Medicine, 312 Anshan west Road, Tianjin 300193, China. 2. Tianjin University of Traditional Chinese Medicine, 312 Anshan west Road, Tianjin 300193, China. Electronic address: yaowufenxi001@sina.com. 3. Tianjin University of Traditional Chinese Medicine, 312 Anshan west Road, Tianjin 300193, China. Electronic address: ycq-4@163.com.
Abstract
BACKGROUND: In recent years, using metabolomics technology to study hypertension has made some progress. However, in actual clinical studies, there are few studies on hypertension related metabonomics with human urine as samples. In this study, the urine samples of patients with essential hypertension (EH) were studied by comparing with healthy people to explore the changes of urine metabolites between hypertensive patients and healthy people in order to find potential biomarkers and metabolic pathways. METHODS: An ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS) technology was used to analyze the urine metabolites of 75 cases of essential hypertension group (EH) and 75 cases of healthy control group (HC). RESULTS: According to the PLS-DA pattern recognition analysis, substances with significant differences (P < .05) between the EH group and the HC group were screened out, including 10 potential biomarkers such as L-methionine. The metabolic pathways involved were amino acid metabolism, fatty acid metabolism steroid hormone, biosynthesis and oxidative stress. CONCLUSION: The non-targeted metabolomics based on UPLC-Q-TOF/MS technology can effectively identify the differential metabolites of potential biomarkers in the urine of essential hypertensive patients and provide a theoretical basis for the treatment of clinical hypertension.
BACKGROUND: In recent years, using metabolomics technology to study hypertension has made some progress. However, in actual clinical studies, there are few studies on hypertension related metabonomics with human urine as samples. In this study, the urine samples of patients with essential hypertension (EH) were studied by comparing with healthy people to explore the changes of urine metabolites between hypertensivepatients and healthy people in order to find potential biomarkers and metabolic pathways. METHODS: An ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS) technology was used to analyze the urine metabolites of 75 cases of essential hypertension group (EH) and 75 cases of healthy control group (HC). RESULTS: According to the PLS-DA pattern recognition analysis, substances with significant differences (P < .05) between the EH group and the HC group were screened out, including 10 potential biomarkers such as L-methionine. The metabolic pathways involved were amino acid metabolism, fatty acid metabolism steroid hormone, biosynthesis and oxidative stress. CONCLUSION: The non-targeted metabolomics based on UPLC-Q-TOF/MS technology can effectively identify the differential metabolites of potential biomarkers in the urine of essential hypertensivepatients and provide a theoretical basis for the treatment of clinical hypertension.
Authors: Jiahong Sun; Min Zhao; Liu Yang; Xue Liu; Lucia Pacifico; Claudio Chiesa; Bo Xi Journal: Int J Hypertens Date: 2021-08-24 Impact factor: 2.420
Authors: Valentin Rousson; Daniel Ackermann; Belen Ponte; Menno Pruijm; Idris Guessous; Claudia H d'Uscio; Georg Ehret; Geneviève Escher; Antoinette Pechère-Bertschi; Michael Groessl; Pierre-Yves Martin; Michel Burnier; Bernhard Dick; Murielle Bochud; Bruno Vogt; Nasser A Dhayat Journal: PLoS One Date: 2021-07-08 Impact factor: 3.240
Authors: Paula J Martinez; Marta Agudiez; Dolores Molero; Marta Martin-Lorenzo; Montserrat Baldan-Martin; Aranzazu Santiago-Hernandez; Juan Manuel García-Segura; Felipe Madruga; Martha Cabrera; Eva Calvo; Gema Ruiz-Hurtado; Maria G Barderas; Fernando Vivanco; Luis M Ruilope; Gloria Alvarez-Llamas Journal: J Mol Med (Berl) Date: 2020-09-11 Impact factor: 4.599